No Data
No Data
Executive Reshuffles: INTC, ZS, ETSY and SEDG
Beam Therapeutics Announces New Data From BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting
Express News | Beam Therapeutics: All 7 Patients Treated With Beam-101 Achieved Durable Increases in Fetal Hemoglobin, Reductions in Sickle Hemoglobin
Express News | Beam Therapeutics Announces New Data From Beacon Phase 1/2 Clinical Trial of Beam-101 in Sickle Cell Disease at Ash Annual Meeting
Express News | Beam Therapeutics: Initial Safety Profile Consistent With Busulfan Conditioning and Autologous Hematopoietic Stem Cell Transplantation
Express News | Beam Therapeutics Shares Are Trading Higher. The Company Appointed a New CFO